CuraSen Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$10.9M
- Investors
-
10
CuraSen General Information
Description
Operator of a biopharmaceutical company intended for the development of novel treatments for neurodegenerative diseases. The company engages in developing small molecules that target innate homeostatic pathways and develops drugs for neurodegenerative disorders like inflammation, proteinopathy, neuronal atrophy, Alzheimer's, and Parkinson's diseases, enabling healthcare professionals to effectively treat patients with neurodegenerative diseases.
Contact Information
Website
www.curasen.comCorporate Office
- 733 Industrial Road
- San Carlos, CA 94070
- United States
Corporate Office
- 733 Industrial Road
- San Carlos, CA 94070
- United States
CuraSen Timeline
CuraSen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 24-Aug-2026 | $10.9M | Completed | Clinical Trials - Phase 2 | ||
| 5. Later Stage VC (Series B) | 18-Sep-2024 | Completed | Clinical Trials - Phase 2 | |||
| 4. Secondary Transaction - Private | 01-Nov-2023 | Completed | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC (Series A) | 11-Oct-2023 | Completed | Clinical Trials - Phase 2 | |||
| 2. Later Stage VC (Series A) | 21-Oct-2021 | $18M | $72.5M | Completed | Clinical Trials - Phase 1 | |
| 1. Later Stage VC (Series A) | 17-Oct-2018 | $54.5M | $54.5M | Completed | Pre-Clinical Trials |
CuraSen Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A Prime |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
CuraSen Comparisons
Industry
Financing
Details
CuraSen Competitors (19)
One of CuraSen’s 19 competitors is NeuroNascent, a Venture Capital-Backed company based in Clarksville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NeuroNascent | Venture Capital-Backed | Clarksville, MD | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA | ||||
| Neurogene | Formerly VC-backed | New York, NY | ||||
| Neurona Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Alector | Formerly VC-backed | South San Francisco, CA |
CuraSen Patents
CuraSen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025188807-A1 | Combination compositions and methods of use | Pending | 06-Mar-2024 | ||
| WO-2025188807-A8 | Combination compositions and methods of use | Pending | 06-Mar-2024 | ||
| US-20260207568-A1 | Compositions and methods for improving neurological diseases and disorders | Pending | 21-Dec-2022 | ||
| WO-2024137506-A1 | Compositions and methods for improving neurological diseases and disorders | Inactive | 21-Dec-2022 | ||
| US-20260207533-A1 | Methods for treating various conditions and indications with agonists and antagonists | Pending | 21-Dec-2022 | A61K31/138 |
CuraSen Signals
CuraSen Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ABRDN Emerging Markets Equity Income | Asset Manager | Minority | ||
| abrdn Healthcare Investors | Hedge Fund | Minority | ||
| Alzheimers Drug Discovery Foundation | Not-For-Profit Venture Capital | Minority | ||
| Alta Partners | Venture Capital | Minority | ||
| Chiesi Ventures | Corporate Venture Capital | Minority |
CuraSen FAQs
-
When was CuraSen founded?
CuraSen was founded in 2013.
-
Where is CuraSen headquartered?
CuraSen is headquartered in San Carlos, CA.
-
What is the size of CuraSen?
CuraSen has 20 total employees.
-
What industry is CuraSen in?
CuraSen’s primary industry is Drug Discovery.
-
Is CuraSen a private or public company?
CuraSen is a Private company.
-
What is CuraSen’s current revenue?
The current revenue for CuraSen is .
-
How much funding has CuraSen raised over time?
CuraSen has raised $107M.
-
Who are CuraSen’s investors?
ABRDN Emerging Markets Equity Income, abrdn Healthcare Investors, Alzheimers Drug Discovery Foundation, Alta Partners, and Chiesi Ventures are 5 of 10 investors who have invested in CuraSen.
-
Who are CuraSen’s competitors?
NeuroNascent, Alzheon, Neurogene, Neurona Therapeutics, and Alector are some of the 19 competitors of CuraSen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process